Endo Gets Untitled Letter for Omitting Heart Risks in Brochure for Prostate Cancer Drug
Endo Pharmaceuticals received an FDA untitled letter for omitting cardiovascular (CV) and other serious risks associated with its prostate cancer drug Vantas in a 12-page caregiver brochure.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.